After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021. The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %). Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871157PMC
http://dx.doi.org/10.34172/jcvtr.2022.31583DOI Listing

Publication Analysis

Top Keywords

heart transplant
12
transplant recipients
8
patients covid-19
8
heart transplantation
8
covid-19
6
covid-19 heart
4
recipients solid
4
solid organ
4
organ transplantation
4
patients
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!